NeoGenomics, Inc.
NeoGenomics, Inc. (Nasdaq: NEO) provides oncology diagnostic testing and consultative services through a network of cancer-focused laboratories in the United States and the United Kingdom. Its services include cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular and next-generation sequencing tests,… From the company’s description.
In fiscal 2025, NeoGenomics, Inc. reported revenue of $727.33M, up 10.1% from fiscal 2024, and a net loss of $108.03M. Its operating margin was −15.9%, and operations generated $5.23M in cash. Over the twelve months to Jun 30, 2026, revenue was $766.29M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NeoGenomics, Inc. does
In the company’s own words
NeoGenomics, Inc. (Nasdaq: NEO) provides oncology diagnostic testing and consultative services through a network of cancer-focused laboratories in the United States and the United Kingdom. Its services include cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular and next-generation sequencing tests, molecular residual disease testing, and pathology interpretation and consultation. Customers include community pathology and oncology practices, hospitals, reference laboratories, academic centers, pharmaceutical companies, and biotechnology firms. The company also supports pharmaceutical research and clinical trials with laboratory testing, biomarker analysis, and related scientific services, and licenses de-identified oncology data. It operates as one reportable segment encompassing its range of services. Its test portfolios include PanTracer, Neo Comprehensive, and NeoTYPE; its Inivata acquisition added liquid-biopsy capabilities, including the RaDaR test for detecting residual disease and recurrence in solid tumors. As of December 31, 2025, NeoGenomics had approximately 2,500 full-time equivalent employees, including contracted pathologists.
Company details
- Sector
- Health Care
- Industry (SIC)
- Professional Services
- Headquarters
- FORT MYERS, FL
- Fiscal year end
- December
- CIK
- 1077183
- SIC
- 8734
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NeoGenomics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NeoGenomics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
NeoGenomics, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of NeoGenomics, Inc.’s debt, $0.56M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.75%, maturing 2032 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NeoGenomics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NeoGenomics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NeoGenomics, Inc.'s last four quarterly filings that the numbers alone won't show?”